Low molecular weight heparin is associated with greater cytokine production in a stimulated whole blood model

Shock

Volumn 10, Issue 3, 1998, Pages 192-197

  Call, Douglas R ^a   Remick, Daniel G ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Med Sci I   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BACTERIAL POLYSACCHARIDE; CYTOKINE; DALTEPARIN; HEPARIN; HYDROGEN PEROXIDE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 8; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR ALPHA; ZYMOSAN;

ARTICLE; BLOOD; CHEMISTRY; DRUG EFFECT; HUMAN; METABOLISM; MOLECULAR WEIGHT;

ANTICOAGULANTS; BLOOD; CYTOKINES; DALTEPARIN; HEPARIN; HUMANS; HYDROGEN PEROXIDE; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-1; INTERLEUKIN-8; MOLECULAR WEIGHT; PHYTOHEMAGGLUTININS; POLYSACCHARIDES, BACTERIAL; TUMOR NECROSIS FACTOR-ALPHA; ZYMOSAN;

EID: 0032162028     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199809000-00007     Document Type: Article

References (31)

1. Lindahl U, Lidholt K, Spillmann D, Kjellen L: More to "heparin" than anticoagulation. Thromb Res 75:1-32, 1994.
2. Verstraete M: Heparin and thrombosis: A seventy year long story. Haemostasis 20:4-11, 1990.
3. Lotto A, Colombo A, Talarico G, Fratianni G, Lettino M: Heparin and secondary prevention of acute myocardial infarction. Haemostasis 20: 132-141, 1990.
4. Daubener W, Nockemann S, Gutsche M, Hadding U: Heparin inhibits the antiparasitic and immune modulatory effects of human recombinant interferon-gamma. Eur J Immunol 25:688-692, 1995.
5. Jones A, Geczy CL: Thrombin and factor Xa enhance the production of interleukin-1. Immunology 71:236-241, 1990.
6. El Habbal MH, Smith L, Elliott MJ, Strobel S: Effect of heparin anticoagulation on neutrophil adhesion molecules and release of IL8: C3 is not essential. Cardiovasc Res 30:676-681, 1995.
7. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP: Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 82:3253-3258, 1993.
8. Borowiec JW, Hagman L, Totterman TH, Pekna M, Venge P, Thelin S: Circulating cytokines and granulocyte-derived enzymes during complex heart surgery: A clinical study with special reference to heparin-coating of cardiopulmonary bypass circuits. Scand J Thorac Cardiovasc Surg 29: 167-174, 1995.
9. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM: Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 106:1008-1016, 1993.
10. Steinberg BM, Grossi EA, Schwartz DS, et al: Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann Thorac Surg 60:525-529, 1995.
11. Engstad CS, Gutteberg TJ, Osterud B: Modulation of blood cell activation by four commonly used anticoagulants. Thromb Haemost 77:690-696, 1997.
12. Coccheri S: Low molecular weight heparins: An introduction. Haemostasis 20:74-80, 1990.
13. Hemker H, Beguin S, Pieters J, Lindhout T: The ex vivo correlate of the antithrombotic action of heparin. Ann NY Acad Sci 556:146-157, 1989.
14. Barzu T, van Rijn J, Petitou M, Tobelem G, Caen J: Heparin degradation in the endothelial cells. Thromb Res 47:601-609, 1987.
15. Palareti G, Legnani C, Bianchini B, et al: Pharmacodynamic effects on blood coagulation of a new low molecular weight heparin (alfa-LMWH) in healthy volunteers and gynecological surgery patients. Int Angiol 8:47-52, 1989.
16. Espevik T, Nissen-Meyer J: A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95:99-105, 1986.
17. Wollenberg GK, DeForge LE, Bolgos G, Remick DG: Differential expression of tumor necrosis factor and interleukin-6 by peritoneal macrophages in vivo and in culture. Am J Pathol 143:1121-1130, 1993.
18. Aarden LA, De Groot ER, Schaap OL, Lansdorp PM: Production of hybridoma growth factor by human monocytes. Eur J Immunol 17:1411-1416, 1987.
19. DeForge LE, Remick DG: Sandwich ELISA for detection of picogram quantities of interleukin-8. Immunol Invest 20:89-97, 1991.
20. Hoffman M, Cooper ST: Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms. Blood Mol Dis 21:156-167, 1995.
21. Van Deuren M, Dofferhoff ASM, Van der Meer JWM: Cytokines and the response to infection. J Pathol 168:349-356, 1992.
22. Lantz M, Thysell H, Nilsson E, Olsson I: On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest 88:2026-2031, 1991.
23. Keuter M, Dharmana E, Gasem MH, et al: Patterns of proinflammatory cytokines and inhibitors during typhoid fever. J Infect Dis 169:1306-1311, 1994.
24. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P: Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17:975-978, 1989.
25. McMurray J, Abdullah I, Dargie HJ, Shapiro D: Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J 66:356-358, 1991.
26. Jacobs CA, Beckmann MP, Mohler K, Maliszewski CR, Fanslow WC, Lynch DH: Pharmacokinetic parameters and biodistribution of soluble cytokine receptors. Int Rev Exp Pathol 34:123-135, 1993.
27. Van Deuren M, Van der Ven-Jongekrijg MJ, Keuter M, Demacker PNM, Van der Meer JWM: Cytokine production in whole blood cultures. J Int Fed Clin Chem 5:216-221, 1993.
28. McBride WT, Armstrong MA, McMurray TJ: An investigation of the effects of heparin, low molecular weight heparin, protamine, and fentanyl on the balance of pro- and anti-inflammatory cytokines in in-vitro monocyte cultures. Anaesthesia 51:634-640, 1996.
29. Hill GE, Whitten CW, Landers DF: The influence of cardiopulmonary bypass on cytokines and cell-cell communication. J Cardiothorac Vasc Anesth 11:367-375, 1997.
30. Ofosu FA: In vitro and ex vivo activities of CY216: Comparison with other low molecular weight heparins. Haemostasis 20:180-192, 1990.
31. Hunt BJ, Doughty HA, Majumdar G, et al: Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 77:39-43, 1997.